Icatibant Teva

Icatibant acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL injection solution for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for cold‑chain logistics and regulatory support, and ensuring product integrity throughout transport and storage.

Icatibant Teva is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema. - Acute HAE attacks (C1‑inhibitor deficiency): rapid reduction of swelling and pain. - Hereditary angioedema type I attacks: alleviation of edema during episodes. - Hereditary angioedema type II attacks: alleviation of edema during episodes.

Icatibant Teva may be associated with injection‑site reactions and systemic adverse events.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection area. - Redness: localized erythema around the injection site. - Swelling: transient edema at the site. - Headache: mild headache occurring after administration.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Severe abdominal pain: persistent pain that may indicate an adverse gastrointestinal response. - Thrombocytopenia: low platelet count observed in rare cases, monitored by laboratory tests.

When using Icatibant Teva, clinicians should consider several precautionary measures to ensure safe administration. - Pregnancy: safety has not been established; use only if potential benefit justifies risk. - Breastfeeding: unknown safety; weigh benefits against potential infant exposure. - Renal impairment: no dosage adjustment required, but monitor for accumulation. - Concomitant ACE inhibitors: may increase risk of angioedema; observe closely. - Allergy to formulation components: avoid use in patients with known hypersensitivity. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva has a limited interaction profile, but certain drug combinations require attention.

Major Interactions (Avoid): - ACE inhibitors: additive risk of angioedema; avoid concurrent use. - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema; monitor closely.

Moderate Interactions (Monitor Closely): - C1‑inhibitor concentrate: may reduce need for icatibant; monitor clinical response. - Antifibrinolytics (e.g., tranexamic acid): possible additive effect on coagulation; observe. - Other bradykinin pathway modulators: may alter efficacy; assess therapeutic outcome.